Development of a combined live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a sucutaneous administration of a recombinant canarypoxvirus expressing FELV genes.

Study title:

EU record number:

B/BE/99/VW8

Treated organism:

cats

Indication category:

vaccination against feline leukemia virus (FELV)

Genetic modification:

env and gag genes of the type A virus of feline leukemia (FELV)

Method of transfer of nucleic acid of interest:

Canarypoxvirus (ALVAC clone)

Route of administration:

subcutaneous

Locations in Belgium:

Heverlee, Deurne, Merksem, Tournai, Haine St Pierre, Ternat, Boncelles, Beaufays, Mechelen, Alleur

Nr of subjects:

800

Foreseen duration:

8 months

Type of procedure:

Deliberate release only

Notes:

Same genetically modified virus as for dossier B/BE/97/VW9 authorized in 1998

Information for the public

Information related to the decision procedure

B/BE/99/VW8 – Advice of the Division Biosafety and Biotechnology (SBB)

6 October 2000: The SBB issues a positive advice for this trial (the advice is written in French)
B/BE/99/VW8 – Advice of the Regional Competent Authority

17 October 2000: The Regional Competent Minister issues a positive advice
B/BE/99/VW8 - Decision of the Federal Public Service (FINAL DECISION)

24 October 2000: The Federal Public Service Health, Food chain safety and Environment gives a final decision (positive with conditions) for this trial.